Yamazaki et al. constructed an anti-HER2 dual-payload ADC carrying both MMAE and MMAF toxins, which achieved complete remission in breast cancer xenograft models with low HER2 expression and resistance to traditional T-DM1, significantly outperforming the efficacy of either single-payload ADC[139]. Here, ERBB2 is linked to breast carcinoma.